论文部分内容阅读
目的:分析脑钠肽(BNP)联合C反应蛋白(CRP)测定在慢性阻塞性肺疾病(COPD)合并肺心病诊治中的临床意义。方法:回顾性分析2014年1月~2016年12月期间在我院收治的56例COPD合并肺心病患者作为观察组,另选取同期在我院行体检的健康者60例作为对照组,测定比较两组入选者的血浆BNP、血清CRP水平。结果:观察组患者BNP、CRP水平明显高于对照组,P<0.05,差异具有统计学意义。不同病情程度的COPD合并肺心病患者的BNP、CRP水平差异明显,P<0.05,差异具有统计学意义。随着病情的加重患者的BNP、CRP水平也逐渐增高。结论:BNP联合CRP测定可作为诊断及评估治疗COPD合并肺心病效果的依据,其水平高低与患者的病情严重程度相关。
Objective: To analyze the clinical significance of the combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) in the diagnosis and treatment of chronic obstructive pulmonary disease (COPD) complicated with pulmonary heart disease. Methods: A retrospective analysis of 56 cases of COPD patients with pulmonary heart disease treated in our hospital from January 2014 to December 2016 was selected as the observation group. Another 60 healthy people who took physical examination in our hospital during the same period were selected as the control group. Plasma BNP and serum CRP levels were compared between two groups. Results: The levels of BNP and CRP in the observation group were significantly higher than those in the control group, P <0.05, the difference was statistically significant. The levels of BNP and CRP in patients with COPD and pulmonary heart disease with different severity of illness were significantly different, P <0.05, the difference was statistically significant. As the disease progresses in patients with BNP, CRP levels also gradually increased. Conclusion: BNP combined with CRP can be used as a basis for diagnosis and assessment of COPD with pulmonary heart disease. The level of BNP is associated with the severity of the disease.